The EPS beat is non-operational and irrelevant for valuation. The key catalyst is the upcoming BPD Type 2b FDA feedback in H2 2026, which will determine the clinical pathway for ABP-450. Monitor for any FDA guidance that de-risks the biosimilar program; the July financing removes near-term dilution risk but the stock remains a binary event play on regulatory milestones.
Price Chart
Executive Summary
AEON Biopharma reported Q2 2026 EPS of -$0.02, significantly beating the consensus estimate of -$0.33, though this is a pre-revenue clinical-stage biotech where EPS is driven by non-cash fair value changes. The company highlighted a $15.3M July financing extending cash runway into Q1 2027 and progress on its ABP-450 biosimilar program with upcoming FDA feedback. The EPS beat is a mechanical artifact of warrant revaluations, not operational improvement, making the report neutral for the stock.
Key Financial Metrics
Key Facts
- Reported Q2 2026 EPS of -$0.02 vs consensus of -$0.33 (beat).
- Revenue was $0 (pre-revenue clinical-stage company).
- Cash and cash equivalents were $3.4M as of June 30, 2026; a July 2026 public offering added ~$13.6M net proceeds, extending cash runway into Q1 2027.
- Company held a successful BPD Type 2a meeting with FDA and expects Type 2b feedback in H2 2026 to inform clinical study requirements.
- Regained NYSE American compliance on August 3, 2026.
- Net loss for Q2 2026 was $1.155M, compared to a $6.642M net loss in Q2 2025, primarily due to a $4.941M gain from change in fair value of warrants.
Financial Impact
EPS beat of $0.31 vs consensus, but driven by non-cash warrant revaluation; cash position strengthened to ~$17M post-July offering, funding operations into Q1 2027.
Risk Factors
- Pre-revenue company with no approved products; dependent on successful FDA interactions and future financing.
- High cash burn rate ($5.9M operating expenses in Q2 2026) with only ~$17M cash runway into Q1 2027.
- Dilution risk from outstanding warrants (potential $34M additional proceeds if exercised) and large share count increase (26.3M shares vs 12.1M at year-end 2025).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2400 (+0.04%) |
Sep 30, 2026 26d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2400 (−20.00%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2400 (+21.58%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2400 (+21.21%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2400 (−11.31%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2400 (+4.27%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2400 (+19.30%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2400 (+19.92%) |
Jul 14, 2026 14w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2400 (+32.77%) |
Jul 9, 2026 15w ago | S-1/A | $0.5027 $0.2974 | ▲ +40.84% | ▲ +40.71% | $0.2400 (+52.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers